Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE-DPN
NCT07183761Phase 2Recruiting
- Start
- Oct 2025
- Primary completion
- Apr 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in diabetic peripheral neuropathy (DPN) (2 arms). Primary endpoints: Toronto Clinical Scoring System at 24 weeks, Adverse Events at 104 weeks and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT07183761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183761.